These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32103681)

  • 1. Macular atrophy development in neovascular age-related macular degeneration during first year of treatment: Incidence and risk factors.
    Oliveira MA; Farinha C; Rodrigues TM; Martins A; Cachulo MDL; Marques JP; Pires I; Silva R
    Eur J Ophthalmol; 2021 Mar; 31(2):521-528. PubMed ID: 32103681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ
    Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Gune S; Abdelfattah NS; Karamat A; Balasubramanian S; Marion KM; Morgenthien E; Sadda SR
    Ophthalmology; 2020 Apr; 127(4):523-532. PubMed ID: 31718842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.
    Munk MR; Ceklic L; Ebneter A; Huf W; Wolf S; Zinkernagel MS
    Acta Ophthalmol; 2016 Dec; 94(8):e757-e764. PubMed ID: 27417506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
    Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
    Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
    Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.
    Abdelfattah NS; Al-Sheikh M; Pitetta S; Mousa A; Sadda SR; Wykoff CC;
    Ophthalmology; 2017 Feb; 124(2):215-223. PubMed ID: 27863845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
    Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
    Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
    Bro T; Hägg S
    Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MACULAR ATROPHY AND MACULAR MORPHOLOGY IN AFLIBERCEPT-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Kuroda Y; Yamashiro K; Ooto S; Tamura H; Oishi A; Nakanishi H; Miyata M; Hata M; Takahashi A; Wakazono T; Yoshimura N; Tsujikawa A
    Retina; 2018 Sep; 38(9):1743-1750. PubMed ID: 28691937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macular atrophy after aflibercept therapy for neovascular age-related macular degeneration: outcomes of Japanese multicenter study.
    Koizumi H; Yamamoto A; Ogasawara M; Maruko I; Hasegawa T; Itagaki K; Sekiryu T; Okada AA; Iida T
    Jpn J Ophthalmol; 2020 Jul; 64(4):338-345. PubMed ID: 32447586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
    Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
    Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
    Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
    Monés J; Biarnés M;
    Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responses of Types 1 and 2 Neovascularization in Age-Related Macular Degeneration to Anti-Vascular Endothelial Growth Factor Treatment: Optical Coherence Tomography Angiography Analysis.
    Kim JM; Cho HJ; Kim Y; Jung SH; Lee DW; Kim JW
    Semin Ophthalmol; 2019; 34(3):168-176. PubMed ID: 31132283
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
    Steinle NC; Du W; Gibson A; Saroj N
    Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration.
    Eng VA; Rayess N; Nguyen HV; Leng T
    PLoS One; 2020; 15(5):e0232353. PubMed ID: 32369500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen.
    Mantel I; Dirani A; Zola M; Parvin P; De Massougnes S; Bergin C
    Retina; 2019 May; 39(5):906-917. PubMed ID: 29370035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.